NSCLC afatinib clinical trials / studies
Let's collaborate Boehringer Ingelheim

NSCLC afatinib clinical trials / studies

Afatinib* has been extensively investigated as part of the LUX-Lung clinical trial programme.

Afatinib’s Clinical Trials In NSCLC

The approval of afatinib for the treatment of TKI-naïve patients with locally advanced or metastatic, EGFR mutation-positive NSCLC is based on the global Phase III LUX-Lung 3 study1 and its Phase III sister trial in Asia, LUX-Lung 6.2

Afatinib is also indicated for the treatment of patients with locally advanced or metastatic squamous NSCLC that has progressed on or after platinum-based chemotherapy, based on the Phase III LUX-Lung 8 study.3 

The approval of afatinib for the treatment of TKI-pretreated patients is based on the Phase IIB/III LUX-Lung 1 study.4

The following table shows the clinical trials of afatinib in lung cancer; you can find links to further information on this site and published papers.

Filter by:
Show all trials

LUX-Lung 3

Phase III
3
reported

EGFR mutation-positive; first-line

Afatinib vs cisplatin/pemetrexed

LUX-Lung 3
Patients whose tumours harbour EGFR mutations (first-line)

LUX-Lung 6

Phase III
3
reported

EGFR mutation-positive; first-line

Afatinib vs cisplatin/gemcitabine

LUX-Lung 6
Patients whose tumours harbour EGFR mutations (first-line)

LUX-Lung 7

Phase IIb
2b
reported

EGFR mutation-positive; first-line

Afatinib vs gefitinib

LUX-Lung 7
Patients whose tumours harbour EGFR mutations (first-line)

LUX-Lung 8

Phase III
3
reported

Chemotherapy pre-treated squamous cell carcinoma of the lung; second-line

Afatinib vs erlotinib

LUX-Lung 8
Patients who have been pre-treated with platinum-based chemotherapy (second-line)

RealGiDo

Post-approval
PA
published

Afatinib dose adjustment in clinical practice

RealGiDo
Patients whose tumours harbour EGFR mutations (first-line)

GioTag

Post-approval
PA
reported

A real-world study of sequential therapy with afatinib followed by osimertinib in EGFR mutation-positive NSCLC

GioTag
Patients whose tumours harbour EGFR mutations (first-line)

LUX-Lung 5

Phase III
3
published

Part A: Afatinib in chemotherapy and EGFR TKI pre-treated patients

Part B: Afatinib beyond progression; afatinib plus chemotherapy vs chemotherapy only

LUX-Lung 5
Patients who have been treated beyond progression

LUX-Lung 1

Phase IIb/III
2b
3
reported

Chemotherapy and EGFR TKI pre-treated; second/third-line

Afatinib vs placebo

LUX-Lung 1
Patients who have been pretreated with erlotinib/ gefitinib (second/third-line)

LUX-Lung 2

Phase II
2
published

EGFR mutation-positive; first- or second-line

Afatinib 40 mg or 50 mg

LUX-Lung 2
Patients whose tumours harbour EGFR mutations (first-line)

LUX-Lung 4

Phase I/II
1
2
reported

Chemotherapy and EGFR TKI pre-treated; second/third-line; Japanese study

Afatinib

LUX-Lung 4
Patients who have been pretreated with erlotinib/ gefitinib (second/third-line)

Ongoing clinical trials

Afatinib plus cetuximab6-8

The combination of afatinib and cetuximab has been investigated in two Phase Ib clinical studies.6-8 These showed the maximum tolerated dose for the combination to be afatinib 40 mg/day plus cetuximab at either 500 mg/m2 Q2W or 250 mg/m2/week.6 In one of these studies, in 126 patients with stage IIIB/IV EGFR mutation-positive NSCLC who had progressed on erlotinib or gefitinib, ORR was 29% and median PFS was 4.7 months, with no reported difference in ORR or PFS according to T790M status.6,7

In the second study, in 49 patients with squamous NSCLC (n=12), head and neck squamous cell carcinoma (HNSCC; n=15) or other solid tumours (n=22), treatment with afatinib* plus cetuximab resulted in a disease control rate of 75% in patients with squamous NSCLC and 55% in the overall population.6,8

The safety profile of afatinib plus cetuximab was predictable and manageable in both studies. Tolerability-guided dose adjustment of afatinib reduced the frequency and intensity of treatment-related AEs.6

Related information

Advanced/metastatic non-small cell lung cancer in focus

Learn about advances in NSCLC treatment and clinical management. This website is intended for HCPs outside the US and the UK.

NSCLC additional analyses and Real-world evidence

Additional clinical trial and real-world data on use of afatinib in special patient populations. This website is intended for HCPs outside the US and the UK.

References

1

Sequist LV, et al. J Clin Oncol 2013;31(27):3327–34.

2

Wu YL, et al. Lancet Oncol 2014;15(2):213–22.

3

Soria JC, et al. Lancet Oncol 2015;16(8):897–907.

4

Miller VA, et al. Lancet Oncol 2012;13(5):528–38.

5

Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/record/NCT02597946 (Accessed: August 2017).

6

Soria J-C, et al. Poster presented at CSCO 2017 (Poster P24).

7

Clinicaltrials.gov. https://www.clinicaltrials.gov/ct2/show/record/NCT01090011 (Accessed: October 2017).

8

Clinicaltrials.gov. https://www.clinicaltrials.gov/ct2/show/record/NCT02020577 (Accessed: October 2017).

Back to top

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.